- Al Sharpton, Trayvon Martin’s parents rally against Fla. ‘stand your ground’ law
- Hillary Clinton campaign got illicit funds from D.C. scandal figure
- Obama administration backs off plan to cut prescription-drug program
- Tickets linked to stolen passports purchased by Iranian middleman
- More than 3,500 police planned for Boston Marathon
- Ottawa day care suspends 2-year-old for ‘outside’ cheese sandwich
- Liam Neeson tells NYC mayor to ‘man up’ in horse carriage fight
- Real-life Dr. Doolittle to reveal how to talk to animals
- Climate change could bring back smallpox, researchers say
- Shoe-bomb witness to speak from London at N.Y. trial
European drugmakers hit with poor test results
PARIS (AP) - Three top European pharmaceutical companies announced on Tuesday disappointing news from clinical tests on drugs they had hoped would turn out to be big sellers.
France’s Sanofi said its multiple sclerosis drug candidate teriflunomide did not achieve one of its goals in a late-stage clinical trial, while Swiss rival Novartis announced it would terminate trials of its high blood pressure treatment Rasilez for patients with diabetes and renal impairment. Britain-based AstraZeneca abandoned plans to develop a new anti-ovarian cancer drug.
Shares in the three companies underperformed European stock markets _ AstraZeneca lost 2.3 percent and Novartis 1 percent, while Sanofi gained 0.8 percent _ as investors reined in their earnings expectations.
Sanofi said teriflunomide, also known by the trade name Aubagio, worked no better than an older drug, Rebif, in preventing relapses, as the study found “no statistical superiority” between Rebif and either 7 mg or 14 mg doses of teriflunomide. Rebif is marketed by Merck KGaA of Germany.
Sanofi’s Genzyme unit enrolled 324 patients with relapsing forms of MS in a two-year study.
The study was the second of five planned efficacy studies of teriflunomide in MS. Genzyme expects to file an application for marketing approval in the European Union in the first quarter of 2012.
In Basel, Switzerland, Novartis said it was terminating a trial of its high blood pressure treatment Rasilez in high-risk patients with diabetes and renal impairment.
The drugmaker said in a statement that it terminated the study on the recommendation of the independent monitoring committee overseeing the trial. The committee found that patients were unlikely to benefit from treatment with Rasilez, and also identified higher incidences of non-fatal stroke, renal complications and other difficulties.
Rasilez, known as Tekturna in the U.S., had sales of $449 million in the first nine months of 2011 and Novartis expects sales will be negatively affected by the study results going forward. Novartis said that as a precautionary measure it will cease promotion of Rasilez/Tekturna-based products for use in combination with standard anti-hypertension treatments.
Also Tuesday, British drugmaker AstraZeneca PLC said it is abandoning plans to develop a new anti-ovarian cancer drug and that a planed antidepressant has underperformed in tests.
The British drug company said Tuesday that it would take a one-time pre-tax loss of $285 million for the failure of olaparib _ a drug that was meant to fight ovarian cancer.
It added that the underperformance of the antidepressant, known as TC-5214, in tests would cost it another $96.5 million, pre-tax.
TWT Video Picks
By David Keene
Conference showed that the values Reagan cherished still endure
- Hillary Clinton campaign received funds from Jeffrey Thompson
- Kim Jong-un calls for execution of 33 Christians
- Unanimous Senate passes bill on military sex assault to give victims more say in prosecution
- Senate Democrats, Republicans spar over restoring unemployment benefits
- Bill Clinton poses for photo with Bunny Ranch prostitutes
- Atheists sue to remove 'Ground Zero Cross' from 9/11 museum
- U.S. pilot scares off Iranians with 'Top Gun'-worthy stunt: 'You really ought to go home'
- Sharyl Attkisson resigns from CBS after months of talks
- Mitch McConnell on beating tea party: 'We are going to crush them'
- DHS accused of holding U.S. citizen at airport, using emails to pry into her sex life
Pope Francis meets his 'mini-me'
Celebrity deaths in 2014
Winter storm hits states — again